Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eyenovia Inc (NQ: EYEN )

5.630 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.630
Bid (Size) 5.500 (10)
Ask (Size) 6.700 (10)
Prev. Close 5.630
Today's Range 5.630 - 5.630
52wk Range 1.110 - 7.720
Shares Outstanding 9,936,771
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET 
From GlobeNewswire News Releases
Eyenovia Announces FDA Acceptance of the MydCombi NDA
FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021. 
From Business Wire News Releases

Performance

YTD
-10.49%
-10.49%
1 Month
-12.58%
-12.58%
3 Month
+39.01%
+39.01%
6 Month
+61.78%
+61.78%
1 Year
+58.59%
+58.59%

More News

Read More
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
From GlobeNewswire News Releases
Pazanga Healthcare Communications Closes a Robust 2020 with Four New Healthcare Clients
From Business Wire News Releases
Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
From Business Wire News Releases
Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors
From Business Wire News Releases
Eyenovia Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tags Pre/Market Outlook CERC Market News
From Benzinga
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
From Business Wire News Releases
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
From Business Wire News Releases
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.